



#5
AM 1624 10/13/02

PATENT CASE IN0291K2GQ1B1C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

BISHOP ET AL.

For Patent For: TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES

Serial No.: 10/026,751

Filed: December 20, 2001

Examiner: To be assigned

Group: 1624

Date: October 4, 2002

TECH CENTER 1600/2900

RECEIVED
OCT 11 2002

Schering-Plough Corporation
Kenilworth, New Jersey 07033-0530

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Submitted herewith is Applicants' PTO Form 1449. Applicants request that the cited references be made of record in the above-identified Application.

Since no action on the merits has been received as of this mailing, no fee is deemed due for this submission. However, if it is determined that a fee is due, then authorization to change such fee to our Deposit Account No. 19-0365 is hereby given.

Copies of references AK, AL, AO, AP, AQ, BL, BM, BN, BO, BP, BQ, BR, BS, BU, BV are submitted herewith.

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231 ON

October 4, 2002


(DATE OF DEPOSIT)

HENRY C. JEANETTE REG. NO. 30,856
(REGISTERED REPRESENTATIVE)

Henry C. Jeanette October 4, 2002
(SIGNATURE AND DATE)


Copies of the remaining references are not submitted herewith in view of Applicants' submission in parent Application Serial No. 9,350,870. The Examiner is requested to notify the undersigned if another copy of these references is desired.

U.S. 5,393,890, cited on the 1449 form, is directed to compounds of the formula:




wherein R can be H, chloro or methoxy; Y can be, amongst others, -CH=CH-, -CH₂CH₂-, -OCH₂, and -SCH₂-; A can be, amongst others, pyridine (see column 2 at about line 27); X can be, amongst others, -CO- or -SO₂-; and Q can be, amongst others, phenyl, piperidinyl or thienyl.


WO88/03138, cited on the 1449 form, discloses compounds of the formula:




wherein: one of a, b, c, and d can be N; X can be C or N; Z can be O or S; and R can be, amongst others, an alkyl group which alkyl group can be substituted with, amongst others, aryl, -N(R¹⁰)₂ (wherein R¹⁰ can be H), -OR¹² (wherein R¹² can be H), or a group D which D group can be, amongst others, the substituent



U.S. 5,089,496, cited on the 1449 form, discloses compounds of the formula:




wherein R can be alkyl substituted with a heterocyclic N-oxide group of the formula



wherein Y represents N⁺-O⁻. R can also be alkyl substituted with -OR¹² or -N(R¹⁰)₂ wherein R¹² and R¹⁰ can be H. (See Column 3 at about lines 37 to about 43).

U.S. 5,089,496, in Column 74, discloses the compounds:




wherein the substituents can be, for example:

R ³	R ⁴	R	Z
-Cl	-H	-CH ₂ OC ₂ H ₅	O
-Cl	-H	-CH(CH ₃)CH ₃	O
-Cl	-H	-C(O)CH ₃	O
-H	-Cl	-CH ₂ OCH ₃	O
-CH ₃	-H	-CH ₂ OCH ₃	O
-H	-H	-CH ₂ OCH ₃	O
-F	-H	-CH ₂ OCH ₃	O
-Cl	-H	-CH(OH)CH ₃	O


(see also Column 76 wherein, for example, R³ is -Cl, R⁴ is -H, Z is O and R is -CH₂CH=CH₂ or C(CH₃)₂OCH₃).

U.S. 5,089,496 also discloses the compounds:




in Example 9 in Column 84.

U.S. 5,089,496 also discloses the compound:






at the top of Column 86.


In Column 93 (the 2nd, 3rd and 4th values for R), U.S. 5,089,496 further discloses the compounds:




wherein R can be:



In addition, Claim 1 of U.S. 5,089,496 is directed to compounds of the formula:




wherein: one of a, b, c, and d can be N; Z can be O or S; and R can be, amongst others, an alkyl group which alkyl group can be substituted with, amongst others, aryl, -N(R¹⁰)₂ (wherein R¹⁰ can be H), -OR¹² (wherein R¹² can be H), or a group D which D group can be, amongst others, the substituent




2-, 3- or 4-piperidinyl, or 2- or 3-piperazinyl.

It is believed that Example 20 (column 95) of U.S. 5,089,496 discloses the compounds:




Claim 3 (Column 100) of U.S. 5,089,496, is directed to compounds of Claim 1 wherein R can be, amongst others, alkyl substituted with OR¹² or -N(R¹⁰)₂.

EP 0 495 484, cited on the 1449 form discloses compounds of the formula:




wherein R¹ represents a cyano, carbamoyl, alkylsulfonyl, alkylsulfonyl, tetrazolyl or sulfonic acid group; and R² represents a hydrogen atom, a cyano, phenyl, aralkyl, alkoxy carbonylalkyl, aminoalkylcarbamoylalkyl or lower alkyl group or a group



or X-R⁴, X being an oxygen or sulfur atom, R³ standing for a hydrogen atom or a substituted or unsubstituted lower alkyl, phenyl or aralkyl group, and R⁴ being a substituted or unsubstituted lower alkyl, phenyl or aralkyl group or an aminoalkyl group.

Respectfully submitted,


Henry C. Jeanette
Reg. No. 30,856
Attorney for Applicants
(908) 298-5041

HCJ: ama
Enclosures



#5
Sheet 1 of 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: IN0291K2GQ1B1C	SERIAL NO.: 10/026,751
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: BISHOP et al.		
(Use several sheets if necessary)		FILING DATE: December 20, 2001	GROUP: 1624	

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
AA	4,282,233	8/81	Villani			
AB	4,826,853	5/89	Piwinski et al.			
AC	4,831,042	5/89	Villani			
✓ AD	4,863,931	9/89	Schumacher et al.	514	290	RECEIVED OCT 11 2002
AE	5,089,496	2/92	Piwinski et al.			
AF	5,104,876	4/92	Piwinski et al.			
AG	5,141,851	8/92	Brown et al.			
AH	5,151,423	9/92	Piwinski et al.			
AI	5,393,890	2/28	Masataka Syoji et al.			
AJ	5,665,726	9/97	Piwinski et al.			
✓ AK	5,672,611	9/97	Doll et al.	514	325	
✓ AL	5,684,013	11/97	Afonso et al.	514	290	
AM	5,696,121	12/97	Bishop et al.			
AN	5,700,806	12/97	Doll et al.			
✓ AO	5,703,090	12/97	Afonso et al.	514	290	
✓ AP	5,712,280	1/98	Doll et al.	514	253	
✓ AQ	5,714,609	2/98	Doll et al.	546	93	

FOREIGN PATENT DOCUMENTS


	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	NO
✓ AR	EP 0042544	12/81	Europe				
✓ AS	EP 0270818	6/88	Europe				
✓ AT	EP 0396083	11/90	Europe				
✓ AU	EP 0495484	7/92	Europe				
AV	EP 0535730	4/93	Europe				
AW	WO88/03138	5/88	WIPO				
AX	WO89/10363	11/89	WIPO				
AY	WO90/13548	11/90	WIPO				
AZ	WO92/00293	1/92	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BA	Cell, 65, 1-4 (1991).
BB	J. Biol. Chem., 266 (24) 15575-15578 (1991).
BC	Proc. Natl. Acad. Sci. USA, 87, 3042-3046 (1990).
BD	Proc. Natl. Acad. Sci. USA, 88, 8631-8635 (1991).
BE	Nature, 356, 713-715 (1992).
BF	Proc. Natl. Acad. Sci. USA, 87, 7541-7545 (1990).
BG	J. Biol. Chem., 265, (25) 14701-14704 (1990).
BH	Proc. Natl. Acad. Sci. USA, 87, 7926-7929 (1990).
BI	Cell, 62, 81-88 (1990).
BJ	Biochemistry, 31, 3800-3807.

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 2 of 2

FORM PTO-1440 <i>PATENT & TRADEMARK OFFICE</i> INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTY. DOCKET NO.: IN0291K2GQ1B1C APPLICANT: BISHOP et al.	SERIAL NO.: 10/026,751 FILING DATE: December 20, 2001 GROUP: 1624
---	--	--

U.S. PATENT DOCUMENTS

RECEIVED

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BZ	Science, 260, 1934-1937.
CA	Science, 260, 1937-1942.
CB	Piwinski, et al., J. Med. Chem., 34, (1) 457-461 (1991).
✓ CC	Chem. Abstracts No. 121:53129x91994 for WO94/04561, Brown et. al,
✓ CD	Masci, J. Chem. Soc., Chem. Commun., 1262-1263 (1982).
CE	Masci B. Tetrahedron 45, (9), 2719-2730 (1989).
CF	Sebti, et al., Proc. Ann. Meeting AM Assoc. Cancer Res., 33:A2217 (1992).
✓ CG	Villani, et al., J. Med. Chem., 15, (7) 750-754 (1972).
✓ CH	Billah, et al., Lipids, 26, (12) 1172-1174 91991).
✓ CI	Villani, et al., Arzneim. -Forsh/Drug Res., 36 (11), 1311-1314 (1986) -

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.